Heavy Menstrual Bleeding Market to Register Stunning Growth During the Forecast Period (2023-2032) – DelveInsight | Key Companies – AbbVie, Takeda, Myovant Sciences

Heavy Menstrual Bleeding Market to Register Stunning Growth During the Forecast Period (2023-2032) - DelveInsight | Key Companies - AbbVie, Takeda, Myovant Sciences
Delveinsight Business Research LLP
As per DelveInsight, the Heavy Menstrual Bleeding Market is anticipated to evolve immensely in the coming years owing to the increasing prevalence of heavy menstrual bleeding, rising research & development activities in pharmaceutical treatment domain, and the launch of pipeline therapies in the market.

DelveInsight’s “Heavy Menstrual Bleeding Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Heavy Menstrual Bleeding market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Heavy Menstrual Bleeding drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Heavy Menstrual Bleeding treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Heavy Menstrual Bleeding: An Overview

Heavy Menstrual Bleeding (HMB) (formerly known as menorrhagia) is a common disorder among people who menstruate. It can be related to a number of conditions including problems with the uterus, hormone problems, or other conditions. Traditionally, Heavy Menstrual Bleeding is defined as bleeding in excess of 80 mL per menstrual cycle when measured objectively.

Usually, menstrual bleeding lasts about 4–5 days and the amount of lost blood is small (2–3 tablespoons). However, women who have menorrhagia usually bleed for more than 7 days and lose twice as much blood. Adolescents and young women presenting with Heavy Menstrual Bleeding dating from their menarche are termed as suffering from primary HMB, whereas relatively acute onset HMB occurring in later reproductive life is referred to as secondary HMB.

Heavy Menstrual Bleeding can result from an abnormality of the uterus (polyps, adenomyosis, leiomyoma, malignancy, or hyperplasia), an abnormality of the endometrium, a disorder of ovulation, an iatrogenic cause, an abnormality of coagulation, or some cause not yet recognized.

Heavy Menstrual Bleeding Market Key Facts

  • According to Shaw (2022), although menorrhagia remains a leading reason for gynecologic office visits, only 10-20% of all menstruating women experience blood loss severe enough to be defined clinically as menorrhagia. Most patients with menorrhagia are older than 30 years.

  • According to Tidy (2020), the prevalence of menorrhagia increases with age, peaking in women aged 30-49 years. 5% of women aged 30–49 years in the UK consult their GP each year due to excessive uterine bleeding.

  • According to Hapanagam and Bulmer (2016), in the developed world, an average woman undergoes ∼400 repetitive cycles of monthly menstrual bleeding with the shedding of her superficial endometrial functional layer. In as many as 20–30% of women, this bleeding is excessive and is termed heavy menstrual bleeding (HMB).

  • According to Kocaoz et al. (2019) reported Heavy Menstrual Bleeding prevalence in women varies between 27.2% and 54.0%3-9, making it a common disorder.

  • According to Filho et al. (2021), the prevalence of Heavy Menstrual Bleeding among women of reproductive age ranges from 10% to 30% and is influenced by the approach to assessment and the clinical setting, as well as cultural, social, and age-driven perceptions of what constitutes ‘normal’ menstruation.

Heavy Menstrual Bleeding Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Heavy Menstrual Bleeding pipeline therapies. It also thoroughly assesses the Heavy Menstrual Bleeding market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the market trend for each marketed Heavy Menstrual Bleeding drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Heavy Menstrual Bleeding Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Heavy Menstrual Bleeding epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Heavy Menstrual Bleeding epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Heavy Menstrual Bleeding Epidemiology, Segmented as –

  • Total Prevalent Cases of Heavy Menstrual Bleeding in the 7MM [2019–2032]

  • Total Diagnosed Prevalent Cases of Heavy Menstrual Bleeding in the 7MM [2019–2032]

  • Total Treated Cases of Heavy Menstrual Bleeding in the 7MM [2019–2032]

Heavy Menstrual Bleeding Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Heavy Menstrual Bleeding market or expected to be launched during the study period. The analysis covers the Heavy Menstrual Bleeding market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Heavy Menstrual Bleeding drugs based on their sale and market share.

The report also covers the Heavy Menstrual Bleeding pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Heavy Menstrual Bleeding companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Heavy Menstrual Bleeding Market Will Evolve and Grow by 2032 @ 


Heavy Menstrual Bleeding Therapeutics Analysis

The treatment goal is to control the current episode of heavy bleeding and to reduce menstrual blood loss in subsequent cycles. HMB could be treated with both medical and surgical interventions and both methods are safe, acceptable, and effective. Although hysterectomy is a definitive treatment for heavy menstrual bleeding with or without other gynecologic conditions such as fibroids, adenomyosis, or endometriosis.

The majorly employed treatment alternatives include either pharmacological interventions or surgical treatment. Pharmacological options are further bifurcated into classes such as hormonal therapies, Gonadotropin-releasing hormone (GnRH) agonists, birth control pills, Non-steroidal anti-inflammatory drugs (NSAIDs), and antifibrinolytic medicines. In contrast, surgical options include endometrial ablation, uterine artery embolization (UAE), myomectomy, and hysterectomy.

Heavy Menstrual Bleeding Companies Actively Working in the Therapeutics Market Include

  • AbbVie

  • Takeda

  • MyovantSciences GmbH 

And Many Others

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Heavy Menstrual Bleeding Competitive Intelligence Analysis

4. Heavy Menstrual Bleeding Market Overview at a Glance

5. Heavy Menstrual Bleeding Disease Background and Overview

6. Heavy Menstrual Bleeding Patient Journey

7. Heavy Menstrual Bleeding Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Heavy Menstrual Bleeding Treatment Algorithm, Current Treatment, and Medical Practices

9. Heavy Menstrual Bleeding Unmet Needs

10. Key Endpoints of Heavy Menstrual Bleeding Treatment

11. Heavy Menstrual Bleeding Marketed Therapies

12. Heavy Menstrual Bleeding Emerging Drugs and Latest Therapeutic Advances

13. Heavy Menstrual Bleeding Seven Major Market Analysis

14. Attribute Analysis

15. Heavy Menstrual Bleeding Market Outlook (In US, EU5, and Japan)

16. Heavy Menstrual Bleeding Companies Active in the Market

17. Heavy Menstrual Bleeding Access and Reimbursement Overview

18. KOL Views on the Heavy Menstrual Bleeding Market

19. Heavy Menstrual Bleeding Market Drivers

20. Heavy Menstrual Bleeding Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Trending Healthcare Reports by DelveInsight

Optic Neuritis Market

Optic Neuritis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Optic Neuritis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Optic Neuritis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/